We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Adjustable Gastric Band for Morbid Obesity

By HospiMedica staff writers
Posted on 08 Oct 2007
A new surgical implant is being used for weight reduction and improvement in obesity related health conditions, such as type 2 diabetes, in individuals suffering from morbid obesity.

The Realize Band is intended for use in weight reduction for patients with morbid obesity and is indicated for individuals with a Body Mass Index (BMI) of at least 40, or a BMI of at least 35 with one or more co-morbid conditions. More...
It is intended for use in morbidly obese adult patients who have failed more conservative weight-reduction alternatives, such as supervised diet, exercise, and behavior modification programs.

In the gastric band surgical procedure, a soft, adjustable silicone band is wrapped around the stomach to create two chambers connected by a narrow opening. After the procedure, the upper stomach can only hold about 115 grams of food, which limits food intake, makes patients feel full faster and for a longer period of time, and slows digestion. Once the band is in place, an injection port is attached to the abdominal wall underneath the skin. The Realize injection port allows doctors to inject or remove saline to tighten or loosen the band. The tighter the band, the more quickly the upper stomach fills up and the less food a person can eat. Adjustments are made periodically based on the patient's individual needs. The Realize Band is a product of Ethicon Endo-Surgery (Cincinnati, OH, USA), a Johnson & Johnson company (New Brunswick, NJ, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

"Obesity is a serious disease, and as a company we're committed to providing more than products to address this worldwide epidemic; we provide bariatric solutions that can help people realize their health goals and live longer and healthier lives regardless of which surgical option may be right for them,” said Kevin Lobo, president of Ethicon Endo-Surgery.

The two most common procedures in bariatric surgery are gastric bypass and gastric banding. Most of these procedures are performed via a laparoscope, typically resulting in less pain, fewer complications, and quicker recovery from surgery compared to traditional open surgery. Laparoscopic adjustable gastric banding (LAGB) is also reversible, if necessary.


Related Links:
Ethicon Endo-Surgery
Johnson & Johnson

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.